Mostrar el registro sencillo del ítem

dc.contributor.authorMembrive Jiménez, Cristina
dc.contributor.authorPérez Ramírez, Cristina 
dc.contributor.authorSánchez Martín, Almudena
dc.contributor.authorVieira Maroun, Sayleth
dc.contributor.authorArias Santiago, Salvador Antonio 
dc.contributor.authorRamírez Tortosa, María Carmen 
dc.contributor.authorJiménez Morales, Alberto
dc.date.accessioned2021-05-25T10:18:23Z
dc.date.available2021-05-25T10:18:23Z
dc.date.issued2021-04-12
dc.identifier.citationMembrive Jiménez, C.; Pérez Ramírez, C.; Sánchez Martín, A.; Vieira Maroun, S.; Arias Santiago, S.A.; Ramírez Tortosa, M.d.C.; Jiménez Morales, A. Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis. J. Pers. Med. 2021, 11, 293. [https://doi.org/10.3390/jpm11040293]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68713
dc.descriptionThis work was partly supported by a contract for Cristina Membrive Jimenez from the University of Granada and the Fundacion de Investigacion Biosanitaria de Andalucia Oriental (FIBAO). The Virgen de las Nieves University Hospital Biobank was supported by grants co-funded by ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039).es_ES
dc.descriptionThe results of this research are part of the doctoral thesis that will be presented by Cristina Membrive Jiménez at the University of Granada as part of the doctoral studies in “Pharmacy”.es_ES
dc.description.abstractPsoriasis is a chronic inflammatory skin pathology of autoimmune origin and unknown etiology. There are various therapies for treating it, including a wide range of biopharmaceuticals indicated in moderate-to-severe psoriasis. Depending on their therapeutic target, they are classified as tumor necrosis factor inhibitors (anti-TNF) or cytokine inhibitors (interleukin-12, 23, and 17 antagonists). Although they have proved effective and safe, in clinical practice, many patients show a short- and long-term suboptimal response and even varying degrees of toxicity. This variability in response may be influenced by genetic factors, such as polymorphisms in the genes involved in the pathological environment, metabolism or mechanism of action of the drug that could affect the effectiveness and toxicity of biological therapies. This review assesses pharmacogenetic studies of the impact of genetic factors on response to biopharmaceuticals and toxicity in patients diagnosed with moderate-to-severe psoriasis. The results suggest that polymorphisms detected in the HLA genes, in genes that encode cytokines (TNF, IL genes, TNFAIP3), transporters (PDE3A-SLCO1C1, SLC12A8), receptors (TNFRSF1B, CD84, FCGR2A and FCGR3A, IL17RA, IL23R, TLR genes, PGLYRP4) and associated proteins (TNFAIP3, LY96, TIRAP, FBXL19), as well as other genes implicated in the pathogenesis of psoriasis (CDKAL1, CARD14, PTTG1, MAP3K1, ZNF816A, GBP6, CTNNA2, HTR2A, CTLA4, TAP1) can be used in the future as predictive markers of treatment response and/or toxicity with biological therapies in patients diagnosed with moderate-to-severe psoriasis, tailoring treatment to the individual patient.es_ES
dc.description.sponsorshipUniversity of Granadaes_ES
dc.description.sponsorshipFundacion de Investigacion Biosanitaria de Andalucia Oriental (FIBAO)es_ES
dc.description.sponsorshipERDF funds (EU) from the Instituto de Salud Carlos III PT13/0010/0039es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectPsoriasis es_ES
dc.subjectPharmacogeneticses_ES
dc.subjectBiological therapieses_ES
dc.subjectPolymorphismses_ES
dc.subjectResponsees_ES
dc.subjectBiomarkerses_ES
dc.subjectPersonalized medicinees_ES
dc.subjectAdalimumabes_ES
dc.subjectEtanerceptes_ES
dc.subjectUstekinumabes_ES
dc.titleInfluence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/jpm11040293
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España